{"DataElement":{"publicId":"3269918","version":"1","preferredName":"Patient Risk Mantle Cell Lymphoma International Prognostic Index Eligibility Determination Status","preferredDefinition":"a condition or state at a particular time relating to the risk assessment criteria for an aggressive, usually diffuse non-Hodgkin's lymphoma composed of monomorphic small to medium sized B-lymphocytes (centrocytes) to determine eligibility of patients for medical care programs and services based on a list of five factors that help doctors assess how a non-Hodgkins lymphoma patient might respond to a certain treatment or predict the risk of disease recurrence and survival following therapy.","longName":"3261836v1.0:3269917v1.0","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"3261836","version":"1","preferredName":"Patient Risk Mantle Cell Lymphoma International Prognostic Index Eligibility Determination","preferredDefinition":"information relating to the risk assessment criteria for an aggressive, usually diffuse non-Hodgkin's lymphoma composed of monomorphic small to medium sized B-lymphocytes (centrocytes) to determine eligibility of patients for medical care programs and services based on a list of five factors that help doctors assess how a non-Hodgkins lymphoma patient might respond to a certain treatment or predict the risk of disease recurrence and survival following therapy.","longName":"2233604v1.0:3261834v1.0","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2233604","version":"1","preferredName":"Patient","preferredDefinition":"A person who requires medical care.","longName":"C16960","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D847-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3261834","version":"1","preferredName":"Risk Mantle Cell Lymphoma International Prognostic Index Eligibility Determination","preferredDefinition":"Risk is the potential future harm that may arise from some present action. It is often combined or confused with the probability of an event which is seen as undesirable. (from WIkipedia):An aggressive, usually diffuse non-Hodgkin's lymphoma composed of monomorphic small to medium sized B-lymphocytes (centrocytes).  Most patients present with advanced stage disease with lymphadenopathy, hepatosplenomegaly, and bone marrow involvement.  Gastrointestinal tract is the most commonly affected extranodal site by this type of non-Hodgkin's lymphoma.  The vast majority of cases express the t(11;14)(q13;q32) resulting in the rearrangement of the BCL-1 gene and the overexpression of cyclin D1 mRNA.  -- 2004:A list of five factors that help doctors assess how a non-Hodgkins lymphoma patient might respond to a certain treatment or predict the risk of disease recurrence and survival following therapy.  The factors are: 1) patient's age, 2) stage of disease: an indication of how localized or widespread is the disease, 3) LDH levels: serum levels often correlate with the amount of tumor in the body, 4) the number of extranodal, non-lymphatic sites found, 5) the patient's overall health. (from Lymphoma Research Foundation of America glossary (www.lymphoma.org)):Criteria to determine eligibility of patients for medical care programs and services.","longName":"C17102:C4337:C20118:C25171","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Risk","conceptCode":"C17102","definition":"The potential future harm that may arise from some present action. It is often combined or confused with the probability of an event which is seen as undesirable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Mantle Cell Lymphoma","conceptCode":"C4337","definition":"A non-Hodgkin lymphoma composed of small to medium sized B-lymphocytes (centrocytes). Most patients present with advanced stage disease with lymphadenopathy, hepatosplenomegaly, and bone marrow involvement. The gastrointestinal tract is the most commonly affected extranodal site by this type of non-Hodgkin lymphoma. The vast majority of cases express the t(11;14)(q13;q32) resulting in the rearrangement of the BCL-1 gene and the overexpression of cyclin D1 mRNA.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"International Prognostic Index","conceptCode":"C20118","definition":"A list of five factors that help doctors assess how a non-Hodgkin lymphoma patient might respond to a certain treatment or predict the risk of disease recurrence and survival following therapy.  The factors are: 1) patient's age, 2) stage of disease: an indication of how localized or widespread is the disease, 3) LDH levels: serum levels often correlate with the amount of tumor in the body, 4) the number of extranodal, non-lymphatic sites found, 5) the patient's overall health. (from Lymphoma Research Foundation of America glossary (www.lymphoma.org))","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Eligibility Determination","conceptCode":"C25171","definition":"The act of determining if a subject is suitable for enrollment in a study according specific protocol criteria and procedures.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AA517EE9-E142-4122-E040-BB89AD437D99","latestVersionIndicator":"Yes","beginDate":"2011-08-12","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-08-12","modifiedBy":"ONEDATA","dateModified":"2011-08-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AA517EE9-E153-4122-E040-BB89AD437D99","latestVersionIndicator":"Yes","beginDate":"2011-08-12","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-08-12","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3269917","version":"1","preferredName":"Patient Risk International Prognostic Index Eligibility Status","preferredDefinition":"a condition or state at a particular time used to classify patients into risk groups as part of the randomization process or for purposes of data analysis.","longName":"3269917v1.0","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"35","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"High","valueDescription":"HIGH","ValueMeaning":{"publicId":"2558875","version":"1","preferredName":"HIGH","longName":"2558875","preferredDefinition":"HIGH","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"High","conceptCode":"C25227","definition":"An elevated level or position or degree; greater than normal in degree or intensity or amount.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B308-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AC488515-E4C7-8C62-E040-BB89AD4375E1","beginDate":"2011-09-06","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-09-06","modifiedBy":"ONEDATA","dateModified":"2011-09-06","deletedIndicator":"No"},{"value":"Intermediate","valueDescription":"INTERMEDIATE","ValueMeaning":{"publicId":"2558979","version":"1","preferredName":"INTERMEDIATE","longName":"2558979","preferredDefinition":"Lying between two extremes in time or space or degree.: The degree of abnormality of cancer cells, a measure of differentiation, the extent to which cancer cells are similar in appearance and function to healthy cells of the same tissue type. The degree of differentiation often relates to the clinical behavior of the particular tumor. Based on the microscopic findings, tumor grade is commonly described by one of four degrees of severity. Histopathologic grade of a tumor may be used to plan treatment and estimate the future course, outcome, and overall prognosis of disease. Certain types of cancers, such as soft tissue sarcoma, primary brain tumors, lymphomas, and breast have special grading systems.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intermediate","conceptCode":"C73705","definition":"Lying between two extremes in time or space or degree.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Histologic Grade","conceptCode":"C18000","definition":"The degree of abnormality of cancer cells, a measure of differentiation, the extent to which cancer cells are similar in appearance and function to healthy cells of the same tissue type. The degree of differentiation often relates to the clinical behavior of the particular tumor. Based on the microscopic findings, tumor grade is commonly described by one of four degrees of severity. Histopathologic grade of a tumor may be used to plan treatment and estimate the future course, outcome, and overall prognosis of disease. Certain types of cancers, such as soft tissue sarcoma, primary brain tumors, lymphomas, and breast have special grading systems.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B370-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"REEVESD","dateModified":"2013-10-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AC488515-E4D2-8C62-E040-BB89AD4375E1","beginDate":"2011-09-06","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-09-06","modifiedBy":"ONEDATA","dateModified":"2011-09-06","deletedIndicator":"No"},{"value":"Low","valueDescription":"Low Risk","ValueMeaning":{"publicId":"2957593","version":"1","preferredName":"Low Risk","longName":"2957593","preferredDefinition":"A minimum level or position or degree; less than normal in degree or intensity or amount.: Risk is the potential future harm that may arise from some present action. It is often combined or confused with the probability of an event which is seen as undesirable. (from WIkipedia)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Low","conceptCode":"C54722","definition":"A minimum level or position or degree; less than normal in degree, intensity or amount.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Risk","conceptCode":"C17102","definition":"The potential future harm that may arise from some present action. It is often combined or confused with the probability of an event which is seen as undesirable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7731E68C-E025-7118-E040-BB89AD43735A","latestVersionIndicator":"Yes","beginDate":"2009-10-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-10-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AC488515-E4DD-8C62-E040-BB89AD4375E1","beginDate":"2011-08-12","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-09-06","modifiedBy":"ONEDATA","dateModified":"2011-09-06","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2404650","version":"1","preferredName":"Status","preferredDefinition":"A condition or state at a particular time.","longName":"C25688","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"005AD6E5-057F-6A35-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-09-09","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-09-09","modifiedBy":"ONEDATA","dateModified":"2005-09-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"ECOG CRF:Eastern Cooperative Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AC488515-E4B1-8C62-E040-BB89AD4375E1","latestVersionIndicator":"Yes","beginDate":"2011-09-06","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-09-06","modifiedBy":"ALAIS","dateModified":"2011-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Patient risk classification b","type":"Preferred Question Text","description":"Patient risk classification by Mantle Cell Lymphoma International Prognostic index (MIPI) score","url":null,"context":"CTEP"},{"name":"Alliance Text 1","type":"Alternate Question Text","description":"MCL IPI Score:","url":null,"context":"Alliance"}],"origin":"ECOG CRF:Eastern Cooperative Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"AC488515-E4E7-8C62-E040-BB89AD4375E1","latestVersionIndicator":"Yes","beginDate":"2011-09-06","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-09-06","modifiedBy":"ZHWENDY","dateModified":"2023-01-25","changeDescription":null,"administrativeNotes":"1/25/2023: Added an AQT for Alliance to reuse per CADSR0001963.wz","unresolvedIssues":null,"deletedIndicator":"No"}}